All updated as on -
The market for cancer vaccines was estimated to be worth $4,189 million in 2023 and is anticipated to grow to $7,309 million by 2030, a CAGR of 13.6%.
Medicines regarded as biological response modifiers include cancer vaccinations. These biological response modifiers function by boosting the body's defenses against cancer. Cancer vaccines come in two varieties: preventive cancer vaccines and therapeutic cancer vaccines. In order to prevent cancer, healthy people are given preventive cancer vaccinations. Patients with cancer are given therapeutic cancer vaccines to boost their immune system's ability to combat the disease. Cancer vaccinations can be given intravenously (IV) to both adults and children.
The market is expanding as a result of factors such the increased incidence of cancer, rising vaccination rates, and the emphasis on tailored vaccines among the major market participants. Additionally, it is projected that increased government financing and investment in vaccine development would fuel market expansion. For instance, the UK government announced in January 2023 that it will invest USD 25.13 (£20 billion) on expanding R&D for vaccine development. Vaccines are a crucial component of the emerging area of immunotherapy, which has shown great promise as a form of treatment.
The main factors driving the growth of the cancer vaccines market are an increase in the number of cancer patients, an increase in the geriatric population, an increase in patient awareness of cancer therapy, an increase in the use of cancer vaccines in combination with other therapies, an increase in the prevalence of human papillomavirus (HPV) infections, and an increase in manufacturer investments and government funding in the development of cancer vaccines. Other factors that support market expansion include technological advancements in cancer vaccines, the introduction of innovative cancer vaccines, an increase in health care services and spending, and a rise in the uptake of preventative and therapeutic vaccines. In addition, rising tobacco use and unhealthful eating patterns are major contributors to the rise in cancer cases, which is fueling demand for cancer vaccinations. However, it is projected that the market expansion will be constrained by the high cost of creating cancer vaccines and the prolonged manufacturing process needed for a single vaccination.
Innovative vaccines that take advantage of the immune system's capacity to target and eradicate oncolytic cells have been made possible by the discovery and advancement of immune checkpoint inhibitors, adoptive cell treatments, and other immunotherapeutic techniques. Moreover, the creation of novel vaccinations has been greatly aided by technological improvement. Next-generation sequencing, high-throughput screening, and bioinformatics methods have made it possible to identify and characterize tumor-specific antigens and create more specialized vaccinations. The efficiency and safety of vaccinations have also improved as a result of developments in vaccine delivery technologies, such as viral vectors and nanoparticles. Furthermore, more effective and precisely targeted vaccines have been developed as a result of technical improvements in research.
Recombinant cancer vaccines are now the largest revenue contributor based on technology, and they are expected to expand significantly over the course of the forecast period. The main drivers of the segment's growth include the rise in recombinant technology acceptance, the use of recombinant vaccines, and the rise in the number of licensed cancer vaccines created using recombinant technology. Due to the high frequency of cervical cancer and the rising number of persons contracting human papillomavirus (HPV) infections, the cervical cancer segment is the largest stakeholder in the global market for cancer vaccines, depending on indication. The segment's growth is also fueled by the aging population, the discovery of cervical cancer drugs, and rising patient knowledge of the disease.
Report Coverage
Global Cancer Vaccines research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Cancer Vaccines report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Cancer Vaccines competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Cancer Vaccines market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Cancer Vaccines market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Cancer Vaccines market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
SANPOWER GROUP CO. LTD. (DENDEREON CORPORATION), Advaxis Inc., Dynavax Technologies Corporation, Generex Biotechnology Corporation, Vaccinogen, Inc., UbiVac, Merck & Co., Inc., Immunocellular Therapeutics, Ltd, Amgen Inc., GlaxoSmithKline plc (GSK), Dendreon Pharmaceuticals LLC. (U.S.), Walvax Biotechnology Co., Ltd. (China), Biomed Lublin S.A. (Poland), Serum Institute of India Pvt. Ltd. (India), Center of Molecular Immunology (Cuba), Organon Teknika Corp., LLC (U.S.), Xiamen Innovax Biotech Co., Ltd. (China).
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Cancer Vaccines market based on the below-mentioned segments:
Global Cancer Vaccines Market, By Type
Preventive Cancer Vaccines
Therapeutic Cancer Vaccines
Global Cancer Vaccines market, By Technology
Dendritic Cells (DC) Cancer Vaccines
Recombinant Cancer Vaccines
Antigen/Adjuvant Cancer Vaccines
Viral Vector & DNA Cancer Vaccines
Global Cancer Vaccines Market, By End User
Pediatrics
Adults
Global Cancer Vaccines market, Regional Analysis
Medicines regarded as biological response modifiers include cancer vaccinations. These biological response modifiers function by boosting the body's defenses against cancer. Cancer vaccines come in two varieties: preventive cancer vaccines and therapeutic cancer vaccines. In order to prevent cancer, healthy people are given preventive cancer vaccinations. Patients with cancer are given therapeutic cancer vaccines to boost their immune system's ability to combat the disease. Cancer vaccinations can be given intravenously (IV) to both adults and children.
The market is expanding as a result of factors such the increased incidence of cancer, rising vaccination rates, and the emphasis on tailored vaccines among the major market participants. Additionally, it is projected that increased government financing and investment in vaccine development would fuel market expansion. For instance, the UK government announced in January 2023 that it will invest USD 25.13 (£20 billion) on expanding R&D for vaccine development. Vaccines are a crucial component of the emerging area of immunotherapy, which has shown great promise as a form of treatment.
The main factors driving the growth of the cancer vaccines market are an increase in the number of cancer patients, an increase in the geriatric population, an increase in patient awareness of cancer therapy, an increase in the use of cancer vaccines in combination with other therapies, an increase in the prevalence of human papillomavirus (HPV) infections, and an increase in manufacturer investments and government funding in the development of cancer vaccines. Other factors that support market expansion include technological advancements in cancer vaccines, the introduction of innovative cancer vaccines, an increase in health care services and spending, and a rise in the uptake of preventative and therapeutic vaccines. In addition, rising tobacco use and unhealthful eating patterns are major contributors to the rise in cancer cases, which is fueling demand for cancer vaccinations. However, it is projected that the market expansion will be constrained by the high cost of creating cancer vaccines and the prolonged manufacturing process needed for a single vaccination.
Innovative vaccines that take advantage of the immune system's capacity to target and eradicate oncolytic cells have been made possible by the discovery and advancement of immune checkpoint inhibitors, adoptive cell treatments, and other immunotherapeutic techniques. Moreover, the creation of novel vaccinations has been greatly aided by technological improvement. Next-generation sequencing, high-throughput screening, and bioinformatics methods have made it possible to identify and characterize tumor-specific antigens and create more specialized vaccinations. The efficiency and safety of vaccinations have also improved as a result of developments in vaccine delivery technologies, such as viral vectors and nanoparticles. Furthermore, more effective and precisely targeted vaccines have been developed as a result of technical improvements in research.
Recombinant cancer vaccines are now the largest revenue contributor based on technology, and they are expected to expand significantly over the course of the forecast period. The main drivers of the segment's growth include the rise in recombinant technology acceptance, the use of recombinant vaccines, and the rise in the number of licensed cancer vaccines created using recombinant technology. Due to the high frequency of cervical cancer and the rising number of persons contracting human papillomavirus (HPV) infections, the cervical cancer segment is the largest stakeholder in the global market for cancer vaccines, depending on indication. The segment's growth is also fueled by the aging population, the discovery of cervical cancer drugs, and rising patient knowledge of the disease.
Report Coverage
Global Cancer Vaccines research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Cancer Vaccines report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Cancer Vaccines competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Cancer Vaccines market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | SANPOWER GROUP CO. LTD. (DENDEREON CORPORATION), Advaxis Inc., Dynavax Technologies Corporation, Generex Biotechnology Corporation, Vaccinogen, Inc., UbiVac, Merck & Co., Inc., Immunocellular Therapeutics, Ltd, Amgen Inc., GlaxoSmithKline plc (GSK), Dendreon Pharmaceuticals LLC. (U.S.), Walvax Biotechnology Co., Ltd. (China), Biomed Lublin S.A. (Poland), Serum Institute of India Pvt. Ltd. (India), Center of Molecular Immunology (Cuba), Organon Teknika Corp., LLC (U.S.), Xiamen Innovax Biotech Co., Ltd. (China). |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Cancer Vaccines Market from 2021 to 2030.
- Market Forecast for Cancer Vaccines Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Cancer Vaccines competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Cancer Vaccines
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Cancer Vaccines market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Cancer Vaccines market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
SANPOWER GROUP CO. LTD. (DENDEREON CORPORATION), Advaxis Inc., Dynavax Technologies Corporation, Generex Biotechnology Corporation, Vaccinogen, Inc., UbiVac, Merck & Co., Inc., Immunocellular Therapeutics, Ltd, Amgen Inc., GlaxoSmithKline plc (GSK), Dendreon Pharmaceuticals LLC. (U.S.), Walvax Biotechnology Co., Ltd. (China), Biomed Lublin S.A. (Poland), Serum Institute of India Pvt. Ltd. (India), Center of Molecular Immunology (Cuba), Organon Teknika Corp., LLC (U.S.), Xiamen Innovax Biotech Co., Ltd. (China).
Primary Target Market
- Market Players of Cancer Vaccines
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Cancer Vaccines market based on the below-mentioned segments:
Global Cancer Vaccines Market, By Type
Preventive Cancer Vaccines
Therapeutic Cancer Vaccines
Global Cancer Vaccines market, By Technology
Dendritic Cells (DC) Cancer Vaccines
Recombinant Cancer Vaccines
Antigen/Adjuvant Cancer Vaccines
Viral Vector & DNA Cancer Vaccines
Global Cancer Vaccines Market, By End User
Pediatrics
Adults
Global Cancer Vaccines market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive cancer vaccines market market research and competitor analysis for your business to help you develop more profound insights into the cancer vaccines market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the cancer vaccines market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.